Biocompatibility of biomaterials - Lessons learned and considerations for the design of novel materials

Schmalz, Gottfried and Galler, Kerstin M. (2017) Biocompatibility of biomaterials - Lessons learned and considerations for the design of novel materials. DENTAL MATERIALS, 33 (4). pp. 382-393. ISSN 0109-5641, 1879-0097

Full text not available from this repository. (Request a copy)

Abstract

Objectives. Biocompatibility of dental materials has gained increasing interest during recent decades. Meanwhile, legal regulations and standard test procedures are available to evaluate biocompatibility. Herein, these developments will be exemplarily outlined and some considerations for the development of novel materials will be provided. Methods. Different aspects including test selection, release of substances, barriers, tissue healing, antibacterial substances, nanoparticles and environmental aspects will be covered. The provided information is mainly based on a review of the relevant literature in international peer reviewed journals, on regulatory documents and on ISO standards. Results. Today, a structured and systematic approach for demonstrating biocompatibility from both a scientific and regulatory point of view is based on a clinical risk assessment in an early stage of material development. This includes the analysis of eluted substances and relevant barriers like dentin or epithelium. ISO standards 14971, 10993, and 7405 specify the modes for clinical risk assessment, test selection and test performance. In contact with breached tissues, materials must not impair the healing process. Antibacterial effects should be based on timely controllable substances or on repellant surfaces. Nanoparticles are produced by intraoral grinding irrespective of the content of nanoparticles in the material, but apparently at low concentrations. Concerns regarding environmental aspects of mercury from amalgam can be met by amalgam separating devices. The status for other materials (e.g. bisphenol-A in resin composites) needs to be evaluated. Finally, the public interest for biocompatibility issues calls for a suitable strategy of risk communication. Significance. A wise use of the new tools, especially the clinical risk assessment should aim at preventing the patients, professionals and the environment from harm but should not block the development of novel materials. However, biocompatibility must always be weighed against the beneficial effects of materials in curing/preventing oral diseases. (C) 2017 Published by Elsevier Ltd on behalf of The Academy of Dental Materials.

Item Type: Article
Uncontrolled Keywords: DENTAL RESIN MONOMERS; IN-VITRO; ULTRAFINE PARTICLES; PROTEIN ADSORPTION; TEMPERATURE RISE; HUMAN PULP; COMPOSITES; CELLS; TOXICITY; RELEASE; Clinical risk assessment; Dentin barrier test; Pulp healing; Antibacterial subtances
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Zahnerhaltung und Parodontologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 14 Dec 2018 13:00
Last Modified: 14 Feb 2019 10:18
URI: https://pred.uni-regensburg.de/id/eprint/182

Actions (login required)

View Item View Item